Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
1. A pharmaceutically acceptable salt of a compound according to Formula (I):
wherein the salt is a 1:1:3 Free Base/HCl/H 2 O adduct and is in a crystalline form, and
wherein the 1:1:3 Free Base/HCl/H 2 O hydrate of the salt is characterized at least by a powder X-ray diffraction peak at any one or more of the following positions: 7.25, 8.31, 8.78, 10.69, 11.96, 12.25, 13.17, 13.74, 16.23, 16.71, 19.26, 19.64, 20.15, 20.57, 20.95, 21.38, 21.69, 22.77, 23.37, 25.14, 25.71, 25.89, 27.66, 28.57, 28.81, 29.17, 29.58, 30.63, 30.94, 32.06, 32.63, 34.14, 36.22, 36.67, and 37.12° 2θ±0.2° 2θ.
2. A pharmaceutically acceptable hydrate of a salt according to claim 1 , wherein the 1:1:3 Free Base/HCl/H 2 O hydrate of the salt is characterized by the following diffraction parameters:
Molecular formula
C 21 H 24 N 5 O 3 S•Cl• 3 (H 2 O)
Molecular weight
516.02
Crystal system
Monoclinic
Space group
P2 1/n
a
13.1388(4) Å
α
102.089(2)°
b
8.9437(3) Å
β
c
21.6376(9) Å
γ
V
2486.24(15)
Å 3
Z
4
Dc
1.379
mg/m 3
μ
0.284
mm −1
Source
Mo-Kα, 0.71073 Å
F(000)
1088
T
120(2)
K
Crystal
colourless prism, 0.39 × 0.16 × 0.12 mm
θ range for
2.982-27.483°
data collection
Completeness
99.3%
Reflections
21028
Unique reflections
5649
R int
0.0307.